GlassScriptPhysician profile
Heidi Mullen
NPI 1851827588
$4,191.25
in general payments reported to CMS, 2019-2025
19 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $815 · 2023: $1,025 · 2024: $1,165 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,153.44 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $571.01 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $280.69 | 2022-2025 | |
| Leo Pharma INC. | $271.28 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $267.70 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $258.39 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $226.88 | 2024-2025 | |
| Lilly USA, LLC | $188.88 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $166.72 | 2021-2025 | Ilumya |
| Organon LLC | $143.26 | 2024-2025 | Vtama, Hadlima |
| Pfizer INC. | $140.13 | 2021-2023 | |
| Galderma Laboratories, L.P. | $111.41 | 2024-2025 | Nemluvio |
| Strata Skin Sciences, INC. | $111.37 | 2022-2025 | Xtrac |
| Ucb, INC. | $109.89 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $86.76 | 2024-2025 | Zoryve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $33.60 | 2023-2024 | Vtama |
| Incyte Corporation | $26.82 | 2021-2024 | Opzelura |
| Tempus Ai, INC | $22.18 | 2024 | |
| Amgen INC. | $20.84 | 2023 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.